Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 674.50
Bid: 674.00
Ask: 675.00
Change: 1.00 (0.15%)
Spread: 1.00 (0.148%)
Open: 674.00
High: 677.50
Low: 672.50
Prev. Close: 673.50
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Venture Fund

8 Nov 2012 07:01

null

Tate & Lyle to expand its global innovation programme through a new £30 million venture fund (Tate & Lyle Ventures II)

Tate & Lyle PLC announced today an investment of up to £30 million over an eight-year period in a new venture capital fund, building on Tate & Lyle's existing venture fund activities.

The new Fund will invest in start-ups and expansion-stage companies in both developed and emerging markets in food sciences and enabling technologies in line with Tate & Lyle's strategy to grow in speciality food ingredients.

The new Fund will be formally launched on 1 January 2013. As with Tate & Lyle's first venture fund, which was launched in April 2006, the new Fund will be independently led and managed by Simon Barnes and David Atkinson.

"This is an important investment in our global innovation programme and represents another step in building Tate & Lyle's platform for long-term growth" said Karl Kramer, President, Innovation and Commercial Development, Tate & Lyle.

Kramer added, "We have seen with our first Fund how beneficial a corporate venturing capability can be. The combination of the new Fund and our internal Open Innovation team will enable us to access the full spectrum of new ideas, technologies and opportunities in the global food science and investment community. This is an investment for long-term growth and, ultimately, will help us deliver more innovative solutions for our customers".

David Atkinson, Tate & Lyle Ventures said, "We are continuing to see a real change in consumer attitudes towards health and nutrition and in particular the growing interest in functional foods. Busy lives, an ageing population and rapid urbanization in emerging markets mean that consumers across the world are looking to food to offer lifestyle solutions and bring added benefits such as fortification and enrichment. New technologies will be instrumental in this convergence as the world's major food companies increasingly reposition themselves with a focus on innovation and health."

Simon Barnes, Tate & Lyle Ventures said, "We will be looking to invest in companies based on strong intellectual property and with strong management teams. As with the first Fund, the independent structure of the new Fund means we can leverage Tate & Lyle's core expertise in helping us to build our portfolio whilst retaining the ability to manage the investments in accordance with sound venture capital principles."

Notes to Editors:

1. For more details on the fund, please contact:

David Atkinson - david.atkinson@tateandlyleventures.com

Simon Barnes - simon.barnes@tateandlyleventures.com

2. The fund will have £30 million of committed capital at closing and is looking to back 8-10 deals over several rounds of finance. Optimal investment sizes are between £2-5 million.

3. Like the first Fund, Tate & Lyle Ventures II will be managed by Circadia Ventures LLP of which Simon Barnes and David Atkinson are the Managing Partners. Circadia Ventures LLP was founded in 2006 and is authorized and regulated by the Financial Services Authority. Simon and David's biographies are:

Simon Barnes

Simon Barnes has a background in life sciences venture capital, first with the London office of Atlas Venture and subsequently with GIMV Venture Capital. He has focused since 1998 on investing in university spin-outs. Simon was trained as a scientist and has a first class degree in Natural Sciences and a PhD from the University of Cambridge. Together with David Atkinson, Simon co-founded Circadia Ventures LLP in 2006. Simon currently sits on the boards of Allylix Inc., Aquapharm BioDiscovery Ltd., Fugeia NV and Lumora Ltd.

David Atkinson

David Atkinson has held a number of senior management positions in the City, with 14 years' experience in equity research focusing on the food processing industry, whilst he alsoco-founded Stamford Partners, the European food and drink industry advisory firm. Together with Simon Barnes, David co-founded Circadia Ventures LLP in 2006. David currently sits on the boards of BioFilm Holdings Ltd., Fugeia NV and Lumora Ltd.

Copyright Business Wire 2012

Date   Source Headline
4th Apr 20184:47 pmBUSDirector/PDMR Shareholding
3rd Apr 201812:27 pmBUSTotal Voting Rights
2nd Mar 201812:04 pmBUSDirector/PDMR Shareholding
15th Feb 20183:44 pmBUSDirector/PDMR Shareholding
14th Feb 20182:55 pmBUSDirector/PDMR Shareholding
13th Feb 20182:03 pmBUSDirector/PDMR Shareholding
8th Feb 20187:00 amBUSTrading Statement
1st Feb 20183:38 pmBUSTotal Voting Rights
18th Jan 20184:12 pmBUSHolding(s) in Company
16th Jan 20187:00 amBUSNick Hampton Appointed Chief Executive of Tate & Lyle PLC
2nd Jan 20189:34 amBUSBlock listing Interim Review
8th Dec 20172:39 pmBUSDirector Declaration
4th Dec 20171:40 pmBUSDirector/PDMR Shareholding
24th Nov 201712:54 pmBUSDirector/PDMR Shareholding
20th Nov 20173:21 pmBUSHolding(s) in Company
16th Nov 20171:17 pmBUSHolding(s) in Company
13th Nov 20171:08 pmBUSHolding(s) in Company
2nd Nov 20177:00 amBUSHalf-year Report
1st Nov 20175:00 pmBUSHolding(s) in Company
19th Sep 20174:16 pmBUSHolding(s) in Company
13th Sep 201710:00 amBUSDirector/PDMR Shareholding
1st Sep 201710:00 amBUSTotal Voting Rights
17th Aug 201711:38 amBUSDirector/PDMR Shareholding
9th Aug 20174:00 pmBUSDirectorate change
3rd Aug 201711:00 amBUSResult of the External Audit Tender
27th Jul 20172:37 pmBUSResult of AGM
27th Jul 20177:00 amBUSTrading Statement
3rd Jul 201712:35 pmBUSTotal Voting Rights
3rd Jul 201712:34 pmBUSBlock listing Interim Review
30th Jun 20173:36 pmBUSDirector/PDMR Shareholding
29th Jun 20173:37 pmBUSDirector/PDMR Shareholding
26th Jun 20173:40 pmBUSDirector/PDMR Shareholding
19th Jun 20174:21 pmBUSAnnual Financial Report
16th Jun 20174:20 pmBUSDirector/PDMR Shareholding
14th Jun 20174:31 pmBUSHolding(s) in Company
1st Jun 20173:40 pmBUSTotal Voting Rights
31st May 20173:11 pmBUSHolding(s) in Company
26th May 201711:40 amBUSHolding(s) in Company
25th May 20177:00 amBUSFinal Results
18th May 20172:40 pmBUSHolding(s) in Company
2nd May 201711:55 amBUSTotal Voting Rights
26th Apr 201710:52 amBUSHolding(s) in Company
11th Apr 20175:05 pmBUSDirector/PDMR Shareholding
4th Apr 20173:09 pmBUSDirector/PDMR Shareholding
4th Apr 201710:53 amBUSTotal Voting Rights
1st Mar 20179:58 amBUSTotal Voting Rights
16th Feb 20176:21 pmBUSTransaction in Own Shares
15th Feb 20176:18 pmBUSTransaction in Own Shares
14th Feb 20175:54 pmBUSTransaction in Own Shares
13th Feb 20176:26 pmBUSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.